title: Identification of miRNAs differentially expressed in clinical stages of human colorectal carcinoma-an investigation in Guangzhou, China.
abstract: Aberrant expression of microRNAs (miRNAs) has been implicated in human cancer, including colorectal cancer (CRC). Such dysregulated miRNAs may have potential as diagnostic markers or therapeutic targets. However, the nature of an association between these miRNAs and clinical stages of CRC is still not clear. To this end, we performed a miRNA profiling of 1547 distinct human miRNAs using 31 samples of tumor and paired normal mucosa obtained from 31 CRC patients. Based on statistical analyses of profiling data, we identified 569 miRNAs that were significantly dysregulated in CRC relative to normal tissues (P<0.05). Among the 569 dysregulated miRNAs, downregulation of 17 was associated with stages II, III, and IV colon and rectal cancers (separate or combined), according to our criteria. We also assessed the potential of these dysregulated miRNAs as diagnostic biomarkers for CRC patients who were without metastasis, and the value of the dysregulated miRNAs for predicting metastasis, lymph node and distant. Their distinct expression patterns in colon and rectal cancers were also examined. Although our findings cannot be immediately applied toward clinical diagnosis, our new study model for determining and assessing the biomarker potential of dysregulated miRNAs should be useful in further research in detection of human CRC.
authors.affiliation: Gastrointestinal Surgery, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
authors.forename: Xue-Hu
authors.initials: XH
authors.lastname: Xu
authors.affiliation: Gastrointestinal Surgery, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
authors.forename: Xiao-Bing
authors.initials: XB
authors.lastname: Wu
authors.affiliation: Gastrointestinal Surgery, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
authors.forename: Shang-Biao
authors.initials: SB
authors.lastname: Wu
authors.affiliation: Department of Experimental Research, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Liu
authors.affiliation: Gastrointestinal Surgery, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Chen
authors.affiliation: Gastrointestinal Surgery, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics; D002681:China; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology*; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D059467:Transcriptome; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs
references.citation: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005390
references.pmid: 18646127
references.citation: PLoS One. 2012;7(4):e34150
references.pmid: 22529906
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
references.pmid: 14973191
references.citation: Mol Cancer. 2006 Jul 19;5:29
references.pmid: 16854228
references.citation: PLoS One. 2012;7(3):e33663
references.pmid: 22479426
references.citation: Cell. 1993 Dec 3;75(5):843-54
references.pmid: 8252621
references.citation: BMC Cancer. 2012 Nov 02;12:505
references.pmid: 23121918
references.citation: World J Gastroenterol. 2009 May 7;15(17):2089-96
references.pmid: 19418581
references.citation: Nat Commun. 2012;3:1291
references.pmid: 23250421
references.citation: Nature. 2005 Jun 9;435(7043):834-8
references.pmid: 15944708
references.citation: Cell. 2005 Jan 14;120(1):15-20
references.pmid: 15652477
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: PLoS One. 2012;7(9):e44398
references.pmid: 22970209
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: Inflamm Bowel Dis. 2011 Jan;17(1):221-31
references.pmid: 20848542
references.citation: Exp Ther Med. 2012 Jun;3(6):1039-1048
references.pmid: 22970014
references.citation: PLoS One. 2012;7(2):e31587
references.pmid: 22348113
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2014-24
references.pmid: 16609010
references.citation: Mol Med. 2013 Feb 08;18:1491-8
references.pmid: 23255074
references.citation: Nat Genet. 2007 May;39(5):673-7
references.pmid: 17401365
references.citation: PLoS One. 2012;7(9):e44206
references.pmid: 22962603
references.citation: BMC Cancer. 2009 Nov 18;9:401
references.pmid: 19922656
references.citation: Med Oncol. 2012 Jun;29(2):1037-43
references.pmid: 21562850
references.citation: Int J Oncol. 2013 Feb;42(2):676-82
references.pmid: 23258531
references.citation: Lancet Oncol. 2012 Jun;13(6):e249-58
references.pmid: 22652233
references.citation: Biochim Biophys Acta. 2013 Feb;1829(2):239-47
references.pmid: 23201159
references.citation: Cancer Res. 2011 Sep 1;71(17):5646-58
references.pmid: 21734013